Table 1 Main characteristics of the included studies
| Â | Study design | Disease/s | participants intervention/participants before | participants control/participants after | Outcome/s analyzed | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study ID | COUNTRY | Study design | Inclusion criteria | Before period (for CBA/ITS) | After period (for CBA/ITS) | Length of post-intervention follow-up period | Â | N | Mean Age (SD) | FEMALE% | N | Mean Age (SD) | FEMALE% | |
Mateo Abad 2020 [18] | Spain | CCT | ≥ 65 years, 2 + chronic conditions (COPD, CHF, diabetes) | - | - | 9–12 months | COPD, CHF, diabetes | 101 | 79.6 (6.9) | 34% | 99 | 79.2 (6.8) | 40% | ED-visits/admissions; Outpatient visits; Hospitalizations; Others |
Snooks 2018 [17] | England (UK) | RCT | General practices within Abertawe Bro Morgannwg University Health Board | - | - | 18 months | Asthma, COPD, diabetes, hypertension | 230,099 | 41.2 (23.4) | 50% | 230,099 | 41.2 (23.4) | 50% | ED-visits/admissions; Outpatient visits; Costs; Others |
Lugo Palacios 2019 [20] | England (UK) | CBA (DiD) | All patients assisted by 2 Clinical Commissioning Groups | Apr 2016-Mar 2017 | Apr 2017-Mar 2018 | 10–13 months | COPD, type II diabetes, heart failure | 5276 COPD, 1877 HF, 13,741 DM | N/A | N/A | 1723 | N/A | N/A | ED-visits/admissions; Outpatient visits; Others |
Jiao 2015 [21] | Hong Kong | CBA (DiD) | Age ≥ 18, ICPC- 2 codes T89/T90, at least one primary clinic attendance before baseline | 1 Aug 2009 - 31 Jul 2010 | Aug 2010 - 31 Jul 2013 | - | Type 2 DM | 9094 | 64.23 (11.05) | 52% | 9094 | 64.29 ± 11.96 | 53% | Mortality; Others |
Wan 2018 [22] | Hong Kong | CBA (DiD) | Age ≥ 18, type 2 DM, no prior CVD or microvascular complications | 1 Aug 2009 - 30 Jun 2011 | Jul 2011-Nov 2015 | - | Type 2 DM | 26,718 | 67.76 (11.73) | 53% | 26,718 | 67.79 (13.64) | 53% | ED-visits/admissions; Outpatient visits; Mortality; Hospitalizations; |
Gupta 2019 [23] | USA | CBA | Patients in UCLA primary care network | CKD before Aug 2016, Dementia and cancer Apr 2017 | CKD Oct-Dec 2016, Dementia and cancer Jun-Sep 2017 | - | CKD, Dementia, Cancer | Dementia: 4348, CKD: 17,172, Cancer: 27,757 | Dementia: 85 (9), CKD: 73.5 (15), Cancer: 62.9 (15) | Dementia: 34%, CKD: 48%, Cancer: 34% | Dementia: 4348, CKD: 17,172, Cancer: 27,757 | Dementia: 85 (9), CKD: 73.5 (15), Cancer: 62.9 (15) | Dementia: 34%, CKD: 48%, Cancer: 35% | Costs |
Soto-Gordoa 2019 [19] | Spain | CCT | Individuals with multimorbidity, ≥ 65 years | 2012 | 2014 | 12 months | Multimorbidity (DM, HF, COPD) | Not prioritized: 2761, Prioritized: 4225 | Not prioritized: 77.98 ± 7.42, Prioritized: 80.17 ± 7.06 | Not prioritized: 36%, Prioritized: 59% | Not prioritized: 2704, Prioritized: 3558 | Not prioritized: 77.61 ± 7.42, Prioritized: 79.2 ± 6.93 | Not prioritized: 36%, Prioritized: 61% | Hospitalizations; Costs; Others; |